https://seekingalpha.com/article/4758658-vistagen-pherine-candidate-proof-of-concept-continues-with-fifth-indication [Seeking Alpha]
VistaGen Therapeutics, Inc. (VTGN)
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vistagen.com
Company Research
Source: Seeking Alpha
Fifth proof-of-concept of pherine drug use was achieved targeting patients with cancer cachexia; Further IND enabling efforts underway to begin phase 2 studies for this program in the United States. The global cancer cachexia market size is projected to reach $3.76 billion by 2032. Two other indications in the pipeline, where VTGN achieved positive phase 2 results for using pherines, were the targeting of patients with Major Depressive Disorder and Hot Flashes Due To Menopause. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Tom Werner Vistagen Therapeutics, Inc. NASDAQ: VTGN ) has been doing well to progress the use of its lead candidate fasedienol
Read more
Impact Snapshot
Event Time:
VTGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTGN alerts
High impacting VistaGen Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VTGN
News
- Vistagen to Present at the 2025 Anxiety and Depression Association ConferenceBusiness Wire
- Vistagen to Participate in Stifel 2025 Virtual CNS ForumBusiness Wire
- Vistagen to Participate in the 45th Annual TD Cowen Healthcare ConferenceBusiness Wire
- Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... [Yahoo! Finance]Yahoo! Finance
- Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update [Yahoo! Finance]Yahoo! Finance
VTGN
Earnings
- 2/13/25 - Beat
VTGN
Sec Filings
- 3/6/25 - Form 8-K
- 2/14/25 - Form SCHEDULE
- 2/14/25 - Form SCHEDULE
- VTGN's page on the SEC website